<DOC>
	<DOCNO>NCT00175019</DOCNO>
	<brief_summary>The purpose study determine long-term safety febuxostat , daily ( QD ) , compare allopurinol reduce serum urate level subject gout .</brief_summary>
	<brief_title>Allopurinol Versus Febuxostat Subjects Completing Phase 3 Trials C02-009 C02-010</brief_title>
	<detailed_description>Uric acid end product purine degradation human . Hyperuricemia , urate concentration serum exceed limit urate solubility ( approximately 7.0 mg/dL ) , common biochemical abnormality . Aberrations multiple mechanism involve production and/or excretion uric acid may increase serum urate concentration , persistent hyperuricemia marker extracellular fluid monosodium urate supersaturation . As , hyperuricemia necessary ( often insufficient ) risk factor monosodium urate crystal deposition tissue fundamental pathophysiological process underlie clinical manifestation gout , chronic disease characterize urate crystal formation deposition joint bone . Gout may progress episodic attack acute inflammatory arthritis disable chronic disorder characterize deform arthropathy ; destructive deposit urate crystal ( tophus ) bone , joint , organ ; structural functional renal impairment due interstitial urate crystal deposition ; urinary tract stone compose entirely partially uric acid crystal . Management gout require chronic treatment aim lower serum urate level subsaturating range ( usually &lt; 6.0 mg/dL ) crystal formation deposition prevent reverse . Febuxostat ( TMX-67 ) non-purine selective xanthine oxidase inhibitor develop orally administer agent management hyperuricemia patient gout . This study originally design initiated subject initially assign 80 mg febuxostat provide 80 mg tablet , administer orally . Subjects could titrate 120 mg , provide one 40 80 mg tablet , Months 2 6 , serum uric acid rise &gt; 6.0 mg/dL ; dose could down-titrated 80 mg serum uric acid decrease &lt; 3.0 mg/dL . The protocol amend add comparator arm , subject randomize 80 120 mg febuxostat allopurinol ( 100 300 mg , dependent renal function ) . The information reflect treatment follow implementation revise protocol .</detailed_description>
	<mesh_term>Febuxostat</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Is receive thiazide diuretic therapy ( subject randomize receive febuxostat ) . Has serum urate level less 8.0 mg/dL take uric acidlowering therapy ( allopurinol febuxostat ) . Has participate clinical study febuxostat administer . Is complete Phase 3 Studies C02009 C02010 . Must experience serious study drugrelated adverse event previous study . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study Has significant medical condition define investigator would interfere treatment , safety , compliance protocol . Is intolerant allopurinol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>uric acid</keyword>
	<keyword>xanthine oxidase</keyword>
	<keyword>hyperuricemia</keyword>
	<keyword>tophus</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>